Bukwang announces patent registration of SOL-804 in 32 countries

[August 05, 2022]

Bukwang Pharmaceutical Co., Ltd. (Bukwang) announced that the composition patent for SOL-804, a prostate cancer treatment of its subsidiary, Dyna Therapeutics, has been recently registered in 6 more countries this year. The patent is registered in 32 countries, Korea, Japan, United States, Eurasia (2 countries), Europe (20 countries), Australia, Mexico, Singapore, South Africa, India, Canada, and Israel. SOL-804 is an improved version of currently available drugs that aim to improve absorption and food effects, which are the weakness of currently available...